Crossmark

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations

Crossref DOI link: https://doi.org/10.1186/s12885-018-4911-7

Published Online: 2018-10-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aiko, Naoto https://orcid.org/0000-0002-3368-2031
Shimokawa, Tsuneo

Miyazaki, Kazuhito

Misumi, Yuki

Agemi, Yoko

Ishii, Mari

Nakamura, Yukiko

Yamanaka, Takeharu

Okamoto, Hiroaki
License Information

Text and Data Mining valid from 2018-10-22
More Information

Article History

Received: 12 September 2017

Accepted: 8 October 2018

First Online: 22 October 2018

Ethics approval and consent to participate

: This retrospective study was conducted in accordance with the ethical standards of the declaration of Helsinki and approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital, Kanagawa, Japan (Approval Number: 17–11-06). The requirement for informed consent was waived due to the retrospective nature of the study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below